Humasis Participates in '2022 AACC'... Unveils New Products Including COVID-19 and Influenza Combo Kit

Humasis AACC Participation Booth.

[Asia Economy Reporter Lee Gwan-joo] Humasis announced on the 3rd that it participated in the '2022 American Association for Clinical Chemistry (AACC)' held in Chicago, USA from the 26th to 28th of last month (local time) and showcased new products.

AACC is the world's largest academic conference in the field of diagnostic testing, and Humasis has been participating since 2012. More than 800 bio companies took part in this year's AACC.

At this AACC, Humasis introduced new products for the first time, including the ▲Humasis COVID-19/Flu Ag Combo Test ▲HUBI DIA. In addition, the 'Humasis COVID-19 RT-qPCR Kit,' the first molecular diagnostic product approved for export by the Ministry of Food and Drug Safety in February, was also introduced at the conference and promoted to global customers.

The 'Humasis COVID-19/Flu Ag Combo Test' is a rapid test kit that can simultaneously test for COVID-19 and influenza, which have similar symptoms. It can detect COVID-19 and influenza virus types A and B simultaneously. This is expected to enable rapid and accurate diagnosis of COVID-19 patients and reduce inefficiencies such as unnecessary isolation.

Another new product, 'HUBI DIA,' is a point-of-care glycated hemoglobin (HbA1c) analyzer that provides accurate analysis results within 4 minutes using a small amount of blood.

A Humasis official stated, “Through this exhibition, we were able to introduce Humasis's diverse portfolio and technological capabilities to buyers from various countries,” adding, “This is expected to expand the existing sales network in the Americas, and we will continue to strive to increase our recognition in the global market.”